20.06.2018
Evotec AG DE0005664809
DGAP-News: RESOLUTIONS OF THE ANNUAL GENERAL MEETING 2018 OF EVOTEC AG
DGAP-News: Evotec AG / Key word(s): AGM/EGM
RESOLUTIONS OF THE ANNUAL GENERAL MEETING 2018 OF EVOTEC AG
20.06.2018 / 15:57
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
* APPROVAL OF ALL AGENDA ITEMS WITH CLEAR MAJORITIES
* CONVERSION OF THE COMPANY INTO EUROPEAN COMPANY (SE) APPROVED
Hamburg, Germany, 20 June 2018:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today
announced that its shareholders approved all proposals the Company's
Management put to vote at the Company's Annual General Meeting 2018 with the
required majorities.
The Management Board presented the Company's progress in the year 2017 and
provided the shareholders with an update and outlook regarding future
developments of the Company in their presentation "Scientific Excellence
meets Operational Excellence".
The strategy and its execution by the members of the Management Board and
the Supervisory Board for the fiscal year 2017 were supported and approved.
Furthermore, shareholders at the Annual General Meeting 2018 voted to
support the conversion into a European Company with a majority of 99.96%.
With this step, Evotec AG will be renamed Evotec SE with the registered seat
and headquarters remaining in Hamburg, Germany, after finalising the
mandatory negotiation process regarding the future arrangements for employee
involvement. This conversion reflects the continuing international focus of
the Evotec Group, which has grown considerably in recent years with
subsidiaries in France, Germany, Italy, Switzerland, the United Kingdom and
the USA.
The Annual General Meeting also approved the appointment of Ernst & Young
GmbH Wirtschaftsprüfungsgesellschaft, Hamburg, as the auditor for fiscal
year 2018. At the ordinary Annual General Meeting 2018 of Evotec AG, 50.84%
of the voting capital was present.
More information on the Company's Annual General Meeting including the
voting results on all agenda items can be found on
https://evotec.com/en/invest/annual-general-meeting.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 80 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and
development partnerships with e.g. with Sanofi in the field of diabetes,
with Pfizer in the field of tissue fibrosis and Celgene in the field of
neurodegenerative diseases. For additional information please go to
www.evotec.com and follow us on Twitter @EvotecAG.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking statements
are neither promises nor guarantees, but are subject to a variety of risks
and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in
events, conditions or circumstances on which any such statement is based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
---------------------------------------------------------------------------
20.06.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard);
Regulated Unofficial Market in Dusseldorf, Hamburg,
Hanover, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
697341 20.06.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT